190 related articles for article (PubMed ID: 36346688)
41. Results of a prospective minimal disseminated disease study in human rhabdomyosarcoma using three different molecular markers.
Sartori F; Alaggio R; Zanazzo G; Garaventa A; Di Cataldo A; Carli M; Rosolen A;
Cancer; 2006 Apr; 106(8):1766-75. PubMed ID: 16544315
[TBL] [Abstract][Full Text] [Related]
42. Hyper-activation of Notch3 amplifies the proliferative potential of rhabdomyosarcoma cells.
De Salvo M; Raimondi L; Vella S; Adesso L; Ciarapica R; Verginelli F; Pannuti A; Citti A; Boldrini R; Milano GM; Cacchione A; Ferrari A; Collini P; Rosolen A; Bisogno G; Alaggio R; Inserra A; Locatelli M; Stifani S; Screpanti I; Miele L; Locatelli F; Rota R
PLoS One; 2014; 9(5):e96238. PubMed ID: 24797362
[TBL] [Abstract][Full Text] [Related]
43. Machine learning for rhabdomyosarcoma histopathology.
Frankel AO; Lathara M; Shaw CY; Wogmon O; Jackson JM; Clark MM; Eshraghi N; Keenen SE; Woods AD; Purohit R; Ishi Y; Moran N; Eguchi M; Ahmed FUA; Khan S; Ioannou M; Perivoliotis K; Li P; Zhou H; Alkhaledi A; Davis EJ; Galipeau D; Randall RL; Wozniak A; Schoffski P; Lee CJ; Huang PH; Jones RL; Rubin BP; Darrow M; Srinivasa G; Rudzinski ER; Chen S; Berlow NE; Keller C
Mod Pathol; 2022 Sep; 35(9):1193-1203. PubMed ID: 35449398
[TBL] [Abstract][Full Text] [Related]
44. Examination of gene fusion status in archival samples of alveolar rhabdomyosarcoma entered on the Intergroup Rhabdomyosarcoma Study-III trial: a report from the Children's Oncology Group.
Barr FG; Smith LM; Lynch JC; Strzelecki D; Parham DM; Qualman SJ; Breitfeld PP
J Mol Diagn; 2006 May; 8(2):202-8. PubMed ID: 16645206
[TBL] [Abstract][Full Text] [Related]
45. The World Health Organization Classification of Skeletal Muscle Tumors in Pediatric Rhabdomyosarcoma: A Report From the Children's Oncology Group.
Rudzinski ER; Anderson JR; Hawkins DS; Skapek SX; Parham DM; Teot LA
Arch Pathol Lab Med; 2015 Oct; 139(10):1281-7. PubMed ID: 25989287
[TBL] [Abstract][Full Text] [Related]
46. Prognosis of children and young adults with newly diagnosed rhabdomyosarcoma metastatic to bone marrow treated on Children's Oncology Group studies.
Schloemer NJ; Xue W; Qumseya A; Luo LY; Hiniker SM; Lautz TB; Rhee DS; Arnold MA; Venkatramani R
Pediatr Blood Cancer; 2023 Dec; 70(12):e30701. PubMed ID: 37783659
[TBL] [Abstract][Full Text] [Related]
47. Prognostic significance and tumor biology of regional lymph node disease in patients with rhabdomyosarcoma: a report from the Children's Oncology Group.
Rodeberg DA; Garcia-Henriquez N; Lyden ER; Davicioni E; Parham DM; Skapek SX; Hayes-Jordan AA; Donaldson SS; Brown KL; Triche TJ; Meyer WH; Hawkins DS
J Clin Oncol; 2011 Apr; 29(10):1304-11. PubMed ID: 21357792
[TBL] [Abstract][Full Text] [Related]
48. OLIG2 is a marker of the fusion protein-driven neurodevelopmental transcriptional signature in alveolar rhabdomyosarcoma.
Raghavan SS; Mooney KL; Folpe AL; Charville GW
Hum Pathol; 2019 Sep; 91():77-85. PubMed ID: 31299267
[TBL] [Abstract][Full Text] [Related]
49. Alveolar rhabdomyosarcoma of the head and neck region in older adults: genetic characterization and a review of the literature.
Yasuda T; Perry KD; Nelson M; Bui MM; Nasir A; Goldschmidt R; Gnepp DR; Bridge JA
Hum Pathol; 2009 Mar; 40(3):341-8. PubMed ID: 18973919
[TBL] [Abstract][Full Text] [Related]
50. Immunohistochemical detection of PAX-FOXO1 fusion proteins in alveolar rhabdomyosarcoma using breakpoint specific monoclonal antibodies.
Azorsa DO; Bode PK; Wachtel M; Cheuk ATC; Meltzer PS; Vokuhl C; Camenisch U; Khov HL; Bode B; Schäfer BW; Khan J
Mod Pathol; 2021 Apr; 34(4):748-757. PubMed ID: 33299109
[TBL] [Abstract][Full Text] [Related]
51. The Polycomb group (PcG) protein EZH2 supports the survival of PAX3-FOXO1 alveolar rhabdomyosarcoma by repressing FBXO32 (Atrogin1/MAFbx).
Ciarapica R; De Salvo M; Carcarino E; Bracaglia G; Adesso L; Leoncini PP; Dall'Agnese A; Walters ZS; Verginelli F; De Sio L; Boldrini R; Inserra A; Bisogno G; Rosolen A; Alaggio R; Ferrari A; Collini P; Locatelli M; Stifani S; Screpanti I; Rutella S; Yu Q; Marquez VE; Shipley J; Valente S; Mai A; Miele L; Puri PL; Locatelli F; Palacios D; Rota R
Oncogene; 2014 Aug; 33(32):4173-84. PubMed ID: 24213577
[TBL] [Abstract][Full Text] [Related]
52. Immunoreactivity against fibroblast growth factor 8 in alveolar rhabdomyosarcoma patients and its involvement in tumor aggressiveness.
Poli E; Barbon V; Lucchetta S; Cattelan M; Santoro L; Zin A; Milano GM; Zanetti I; Bisogno G; Bonvini P
Oncoimmunology; 2022; 11(1):2096349. PubMed ID: 35813575
[TBL] [Abstract][Full Text] [Related]
53. Histology and fusion status in rhabdomyosarcoma.
Rudzinski ER
Am Soc Clin Oncol Educ Book; 2013; ():425-8. PubMed ID: 23714565
[TBL] [Abstract][Full Text] [Related]
54. Molecular Cytogenetics Detect an Unbalanced t(2;13)(q36;q14) and PAX3-FOXO1 Fusion in Rhabdomyosarcoma With Mixed Embryonal/Alveolar Features.
La Starza R; Nofrini V; Pierini T; Pierini V; Zin A; Bisogno G; Cerri C; Caniglia M; Sidoni A; Ludwig K; Mecucci C
Pediatr Blood Cancer; 2015 Dec; 62(12):2238-41. PubMed ID: 26179572
[TBL] [Abstract][Full Text] [Related]
55. KDM3A/Ets1 epigenetic axis contributes to PAX3/FOXO1-driven and independent disease-promoting gene expression in fusion-positive Rhabdomyosarcoma.
Sobral LM; Hicks HM; Parrish JK; McCann TS; Hsieh J; Goodspeed A; Costello JC; Black JC; Jedlicka P
Mol Oncol; 2020 Oct; 14(10):2471-2486. PubMed ID: 32697014
[TBL] [Abstract][Full Text] [Related]
56. Molecular classification of rhabdomyosarcoma--genotypic and phenotypic determinants of diagnosis: a report from the Children's Oncology Group.
Davicioni E; Anderson MJ; Finckenstein FG; Lynch JC; Qualman SJ; Shimada H; Schofield DE; Buckley JD; Meyer WH; Sorensen PH; Triche TJ
Am J Pathol; 2009 Feb; 174(2):550-64. PubMed ID: 19147825
[TBL] [Abstract][Full Text] [Related]
57. Global gene expression profiling of PAX-FKHR fusion-positive alveolar and PAX-FKHR fusion-negative embryonal rhabdomyosarcomas.
Laé M; Ahn EH; Mercado GE; Chuai S; Edgar M; Pawel BR; Olshen A; Barr FG; Ladanyi M
J Pathol; 2007 Jun; 212(2):143-51. PubMed ID: 17471488
[TBL] [Abstract][Full Text] [Related]
58. PAX3-FOXO1 fusion gene in rhabdomyosarcoma.
Linardic CM
Cancer Lett; 2008 Oct; 270(1):10-8. PubMed ID: 18457914
[TBL] [Abstract][Full Text] [Related]
59. Aurora A Kinase Inhibition Destabilizes PAX3-FOXO1 and MYCN and Synergizes with Navitoclax to Induce Rhabdomyosarcoma Cell Death.
Ommer J; Selfe JL; Wachtel M; O'Brien EM; Laubscher D; Roemmele M; Kasper S; Delattre O; Surdez D; Petts G; Kelsey A; Shipley J; Schäfer BW
Cancer Res; 2020 Feb; 80(4):832-842. PubMed ID: 31888889
[TBL] [Abstract][Full Text] [Related]
60. Transactivating mutation of the MYOD1 gene is a frequent event in adult spindle cell rhabdomyosarcoma.
Szuhai K; de Jong D; Leung WY; Fletcher CD; Hogendoorn PC
J Pathol; 2014 Feb; 232(3):300-7. PubMed ID: 24272621
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
